Lalitha Priya Chandrashekhar | Authors


Targeted Treatments Emerge for HER2 Mutations in Lung Cancer

September 20, 2018

HER2 mutations have been identified as another oncogenic driver in the growing list of actionable targets in non–small cell lung cancer. Based on a mounting body of evidence on the impact of HER2 mutations in lung cancer and the growing focus on personalized medicine, the HER2 receptor has gained focus as a potential target for precision medicine treatments for patients with NSCLC.